Cellanyx and clinical collaborators today reported results of a prostate cancer clinical study demonstrating the ability of the company’s live tumor cell phenotypic biomarker test to identify patients with low and intermediate grade prostate cancer at risk of aggressive disease.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,